Opiant Pharmaceuticals (NASDAQ:OPNT) posted its quarterly earnings data on Monday. The technology company reported ($2.77) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by ($1.58), Bloomberg Earnings reports. Opiant Pharmaceuticals had a return on equity of 278.86% and a net margin of 35.68%.

Opiant Pharmaceuticals (NASDAQ OPNT) traded up $0.80 during trading on Tuesday, reaching $31.36. The company’s stock had a trading volume of 31,300 shares, compared to its average volume of 35,379. Opiant Pharmaceuticals has a 12-month low of $5.00 and a 12-month high of $51.90. The company has a market cap of $62.28, a price-to-earnings ratio of 10.57 and a beta of -2.33.

A number of research analysts have weighed in on OPNT shares. ValuEngine downgraded Opiant Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. TheStreet cut Opiant Pharmaceuticals from a “b” rating to a “c+” rating in a research report on Friday, November 24th.

TRADEMARK VIOLATION WARNING: “Opiant Pharmaceuticals (OPNT) Releases Quarterly Earnings Results” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/05/opiant-pharmaceuticals-opnt-releases-quarterly-earnings-results.html.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Earnings History for Opiant Pharmaceuticals (NASDAQ:OPNT)

Receive News & Ratings for Opiant Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.